Menopause HRT FAQs: Estrogen, Progesterone, Safety & Testing

Perimenopause is the transition leading up to menopause. During this time ovarian hormone production fluctuates and menstrual cycles can become irregular. Symptoms can include hot flashes, night sweats, sleep disruption, vaginal symptoms, and changes in well-being.

Menopause is reached after 12 consecutive months without a menstrual period when there is no other cause. The average age is around 51, although the timing varies.

Yes. Perimenopause can be associated with sleep disruption, vasomotor symptoms such as hot flashes and night sweats, and changes in well-being. Poor sleep can also worsen daytime concentration and mood. These symptoms are not specific to menopause, so other causes may still need evaluation.

Routine hormone testing is generally not recommended before starting hormone therapy for typical menopausal symptoms because hormone levels fluctuate substantially during the menopause transition. Evaluation is usually based on symptoms, menstrual changes, age, and medical history, with targeted testing when another diagnosis is being considered.

Systemic estrogen therapy, with progestogen when appropriate, is the most effective treatment for menopausal hot flashes and night sweats. Local vaginal estrogen can help vaginal dryness and related genitourinary symptoms. The treatment chosen depends on the symptoms being treated and the patient's risk profile.

If you still have a uterus and use systemic estrogen, a progestogen is generally needed to reduce the risk of endometrial cancer from unopposed estrogen. Patients who have had a hysterectomy may be able to use estrogen without a progestogen, depending on their individual history.

Systemic estrogen circulates through the bloodstream and is used for symptoms such as hot flashes and night sweats. Local vaginal estrogen delivers a lower dose directly to vaginal tissues and is commonly used when the main concerns are vaginal dryness or other genitourinary symptoms.

Hormone therapy can be considered during perimenopause when symptoms are clinically significant. The appropriate regimen depends on menstrual history, pregnancy possibility, whether the uterus is present, symptoms, medical history, and other factors.

Hormone therapy is not a weight-loss treatment. It may improve symptoms such as night sweats that disrupt sleep, but it should not be prescribed with the expectation that it will directly produce weight loss.

Systemic hormone therapy is usually not recommended for people with certain histories such as breast or endometrial cancer, stroke, heart attack, blood clots, or liver disease, and it is not used during pregnancy. Individual risk assessment is essential because the safest option varies by history and treatment route.

Yes. Oral and transdermal estrogen have different pharmacologic effects and risk profiles. ACOG notes that nonoral routes such as patches, sprays, and rings may have less risk of deep-vein thrombosis than oral therapy. Route selection should be individualized.

No evidence shows that compounded menopausal hormones are safer or more effective than FDA-approved hormone therapy. ACOG recommends FDA-approved hormone therapy over compounded preparations when an approved product can meet the patient's needs.

There is no single duration that fits everyone. ACOG recommends periodically reassessing whether treatment should continue based on symptoms, age, medical history, risks, benefits, and patient preferences. Some patients need therapy longer than others.

Follow-up typically reviews symptom response, side effects, bleeding patterns, blood pressure and relevant health risks, and whether the regimen still fits the patient's goals. New or persistent abnormal bleeding and other concerning symptoms require appropriate evaluation.